Results 41 to 50 of about 8,567 (186)

The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis

Health Science Reports, 2022
Background and Aim Due to the high social and economic burden and also mortality and morbidity caused by coronavirus disease 2019 (COVID‐19) in the past few years, researchers have aimed at finding solutions to suppressing the severity of infection ...
Dena Firouzabadi, Fatemeh Kheshti, Saeed Abdollahifard, Erfan Taherifard, Mohammad Reza Kheshti   +4 more
doaj   +1 more source

Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski, Klaudia Kolonko, Andromachi Giannopoulou, Beata Smela, Elżbieta Olewinska, Kristina Rosa Bolling, Jenifer Sassarini, Lee P. Shulman, Vikram Talaulikar   +8 more
wiley   +1 more source

Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)

JA Clinical Reports, 2019
Background Serotonin syndrome is a rare but potentially severe disease, which is caused by hyperstimulation of serotonin receptors in the central nervous system.
Junko Takata, Tomoko Arashi, Ayako Abe, Shoko Arai, Naoko Haruyama   +4 more
doaj   +1 more source

A Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD): study protocol for a randomized clinical trial and prognosis study

Trials, 2023
Background Major depressive disorder (MDD) with atypical features, namely depression with atypical features (AFD), is one of the most common clinical specifiers of MDD, closely associated with bipolar disorder (BD).
Rubai Zhou, Huifeng Zhang, Shen He, Yi Li, Guiyun Xu, Jinsong Huang, Huaning Wang, Qian Wang, Biao Li, Xuemei Wang, Ningning Chen, Fang Li, Xiaosa Li, Mengjun Liu, Daihui Peng   +14 more
doaj   +1 more source

SNRI und plötzlicher Herztod: ein Mythos? [PDF]

MMW - Fortschritte der Medizin, 2010
In einer Fall-Kontroll-Studie ergeben sich keine Hinweise darauf, dass der selektive Serotonin-Noradrenalin-Wiederaufnahmehemmer Venlafaxin im Vergleich zu anderen gangigen Antidepressiva mit einer erhohten Rate plotzlicher kardialer Todesfalle einhergeht.
openaire   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Asymptomatic syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following duloxetine treatment for pain with depression: Two case reports

Neuropsychopharmacology Reports, 2022
Background Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a common side effect in patients treated with SSRIs and venlafaxine, while there is little information on SIADH in the treatment of duloxetine for pain.
Aoi Sato, Norio Yasui‐Furukori, Yumiko Oda, Misa Yang, Yudai Suzuki, Masataka Shinozaki, Taro Shimizu, Kazutaka Shimoda   +7 more
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Differential and paradoxical roles of new-generation antidepressants in primary astrocytic inflammation

Journal of Neuroinflammation, 2021
Background Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly used new-generation drugs for depression. Depressive symptoms are thought to be closely related to neuroinflammation. In this
Jia-Hui He, Rong-Pei Liu, Yi-Man Peng, Qing Guo, Lan-Bing Zhu, Yi-Zhi Lian, Bei-Lei Hu, Hui-Hui Fan, Xiong Zhang, Jian-Hong Zhu   +9 more
doaj   +1 more source